The Positive Press Coverage Unlikely to Impact Eclipse Resources Corp (ECR) Stock Price

The Positive Press Coverage Unlikely to Impact Eclipse Resources Corp (ECR) Stock Price

Here are some of the news headlines that may have impacted AlphaOne’s rankings:

Press coverage about Eclipse Resources Corp (NYSE:ECR) has trended positive this week, AlphaOne reports. The research firm, a service of Accern, rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eclipse Resources Corp earned a daily sentiment score of 0.43 on AlphaOne’s scale. AlphaOne also assigned media stories about the energy producer an impact score of 33 out of 100, indicating that recent news coverage is unlikely to have an impact on the stock’s share price in the next few days.

Several analysts have commented on the stock. Zacks Investment Research raised shares of Eclipse Resources Corp from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Thursday, February 16th. Barclays PLC reaffirmed a “hold” rating and issued a $3.00 target price on shares of Eclipse Resources Corp in a research note on Wednesday, May 24th. Scotiabank set a $4.00 target price on shares of Eclipse Resources Corp and gave the stock a “hold” rating in a research note on Thursday, March 2nd. Seaport Global Securities raised shares of Eclipse Resources Corp from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $3.50 to $4.00 in a research note on Monday, February 6th. Finally, BMO Capital Markets reissued a “hold” rating and set a $3.00 price objective on shares of Eclipse Resources Corp in a research note on Monday, May 15th. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $3.60. Eclipse Resources Corp (NYSE:ECR) opened at 2.11 on Monday. Eclipse Resources Corp has a one year low of $1.60 and a one year high of $4.42. The firm has a 50-day moving average of $2.20 and a 200-day moving average of $2.48. The firm’s market cap is $554.05 million.

In related news, CFO Matthew R. Denezza sold 63,770 shares of the company’s stock in a transaction dated Tuesday, March 14th. The shares were sold at an average price of $2.24, for a total value of $142,844.80. Following the transaction, the chief financial officer now directly owns 659,786 shares in the company, valued at $1,477,920.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin Ward Hulburt sold 75,000 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $2.50, for a total transaction of $187,500.00. Following the completion of the transaction, the insider now owns 1,321,958 shares in the company, valued at $3,304,895. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 168,770 shares of company stock worth $399,345. 0.13% of the stock is owned by corporate insiders. Eclipse Resources Corp Company Profile

Eclipse Resources Corporation is an independent exploration and production company. The Company is engaged in the acquisition and development of oil and natural gas properties in the Appalachian Basin. The Company is the operator of the Utica Core Area and its Marcellus Project Area. The Ordovician-aged Utica Shale is an unconventional reservoir consisting of organic-rich black shale, with production occurring at vertical depths between 6,000 and 10,000 feet.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “ECR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment